The current coronavirus disease 2019 (COVID-19) pandemic has created challenges for the treatment of patients with cancer.
These patients are at a high risk of contracting COVID-19 because of the following factors: older age (≥65 years), medical comorbidities, and Eastern Cooperative Oncology Group status ≥2.
,
Furthermore, the SGO has stated that use of neoadjuvant chemotherapy may be effective in delaying surgery and hospitalization during the COVID-19 pandemic.
In both cases, the patients underwent 3 cycles of chemotherapy followed by repeat imaging with plans for possible IDS.
Although IDS has been shown to be less morbid than primary cytoreductions, there are still inherent surgical risks.